Simcere Pharmaceutical Group Limited
Pharmaceutical industry · Nanjing, Jiangsu
About Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation-driven Chinese pharmaceutical company founded in 1995 with operational headquarters in Nanjing, Jiangsu province, listed on the Hong Kong Stock Exchange. The company focuses on innovative medicines with its own intellectual property rights and on high-barrier generics, and declares a pipeline of more than 60 innovative projects under development and around 50 marketed products.
Its main therapeutic areas are the central nervous system, with products such as the edaravone and dexborneol injection for stroke; oncology, with the recombinant endostatin Endostar and the world's first subcutaneous PD-L1 inhibitor, envafolimab; autoimmune diseases, with the iguratimod Iremod; and anti-infectives. Simcere combines international licensing, co-development alliances and its own State Key Laboratory of innovative drug technology.
The group maintains R&D centres in Nanjing, Shanghai, Beijing and Boston and a commercial network with thousands of medical representatives in China. For international partners, it is a mid-to-large Chinese pharmaceutical company with its own innovation strategy, based in Nanjing on Xuanwu Avenue.
Its main therapeutic areas are the central nervous system, with products such as the edaravone and dexborneol injection for stroke; oncology, with the recombinant endostatin Endostar and the world's first subcutaneous PD-L1 inhibitor, envafolimab; autoimmune diseases, with the iguratimod Iremod; and anti-infectives. Simcere combines international licensing, co-development alliances and its own State Key Laboratory of innovative drug technology.
The group maintains R&D centres in Nanjing, Shanghai, Beijing and Boston and a commercial network with thousands of medical representatives in China. For international partners, it is a mid-to-large Chinese pharmaceutical company with its own innovation strategy, based in Nanjing on Xuanwu Avenue.